Company Profile
Aprea Therapeutics Stock Price, News & Analysis
- Ticker:
- APRE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.63 USD (+1.85%)
Close
Last updated: August 6, 2026
9.46M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, APRE closed up 1.85% at $0.6325. No new same-company headline was identified in the current news window.
Company overview
DNA Damage Response Oncology Company
Aprea Therapeutics develops precision medicines targeting vulnerabilities in cancer-cell DNA replication and repair.
APR-1051
APR-1051 is a selective WEE1 inhibitor being evaluated in the Phase 1/2 ACESOT-1051 study for advanced solid tumors.
Biomarker-Directed Expansion
Development is expanding in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, where WEE1 dependence may be elevated.
Future catalysts
Additional ACESOT-1051 clinical data are scheduled for presentation at the 2026 ASCO Annual Meeting.
Further APR-1051 clinical updates are expected during the second quarter of 2026.
Recent news
- 01
- 02
- 03
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Source: Aprea Therapeutics
- 04
- 05
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Source: Aprea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aprea Therapeutics (APRE)?
Aprea Therapeutics (APRE) most recently closed at 0.63 USD, a +1.85% move versus the previous session.
What is the market cap of Aprea Therapeutics (APRE)?
Aprea Therapeutics currently has a market capitalization of 9.46M USD on BioPharmSignal.
What does Aprea Therapeutics do?
DNA Damage Response Oncology Company Aprea Therapeutics develops precision medicines targeting vulnerabilities in cancer-cell DNA replication and repair. APR-1051 APR-1051 is a selective WEE1 inhibitor being evaluated in the Phase 1/2 ACESOT-1051 study for advanced solid tumors. Biomarker-Directed Expansion Development is expanding in uterine serous...
On which exchange is APRE stock listed?
Aprea Therapeutics (APRE) is associated with NASDAQ, United States, Biopharma.
What is APR-1051?
Further APR-1051 clinical updates are expected during the second quarter of 2026.
Which conditions is Aprea Therapeutics targeting with APR-1051?
Aprea Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Aprea Therapeutics describe recent progress with APR-1051?
Further APR-1051 clinical updates are expected during the second quarter of 2026.
What is ACESOT-1051?
APR-1051 APR-1051 is a selective WEE1 inhibitor being evaluated in the Phase 1/2 ACESOT-1051 study for advanced solid tumors.